Inhibrx | Investors - News Releases

News Releases

Month Year

Month Year

Dec 6, 2018

Inhibrx Announces Dosing of First Patients in Phase 1 Dose-Escalation Study of INBRX-109, a Novel Multivalent Agonist of Death Receptor 5 (DR5)
Oct 31, 2017

Inhibrx Wins CARB-X Award Of Up To $6.0M To Accelerate Development Of Its Novel Antibody, INBRX-111, To Treat Pseudomonas Infections
Sep 15, 2015

Inhibrx and The Alpha-1 Project Collaborate to Develop a Recombinant Alpha-1 Antitrypsin with Improved Properties

Inhibrx’s AAT-Fc therapeutic should benefit patients with enhanced efficacy and less frequent dosing
Jun 27, 2012

Inhibrx announces an Option & License Agreement with Celgene Corporation for Inhibrx Antibody Program

Show per page

Back To Top